No products in the cart
BPC-157 & TB-500 Blend (10mg)
BPC-157 & TB-500 blend is Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
AKA: BPC 157
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.5355 g/mol
Sequence: L-Valine,glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-Lprolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-;glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyllysyl-L-prolyl-L-alanyl-L- alpha-aspartylL-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
PubChem: CID 108101
AKA: Thymosin Beta 4
Molecular Formula: C212H350N56O78S
Molecular Weight: 4963.506 g/mol
PubChem: CID 16132341
CAS Number: 77591-33-4
Potential of BPC-157 & TB-500 Blend in Wound Repair
BPC-157 and TB-500 have been well studied to promote wound healing, although they use different biochemical pathways. However, research has shown that the two molecules exhibit synergistic effects in the healing process in combination. The synergistic effect of the blend improves the overall flexibility and adjustability in the case of recurring injuries.
BPC-157 & TB-500 peptide blend – Cellular Migration
Fibroblasts and immune cells are crucial for the regulation and execution of successful healing of wounds. Both fibroblasts and immune cells migrate to the site of tissue injury, whereby fibroblasts promote the formation of an extracellular matrix. The movement of these cells is dependent on the protein axin. BPC-157 and TB-500 influence wound healing through their regulation of axin protein.
BPC-157 is known to promote the transcription of the axin gene and thereby increase the expression of the protein. It is known to act at the gene level to increase actin production, whereas TB-500 is an actin-binding protein that sequesters actin in areas where its requirement is maximum for cell movement.
TB-500 enhances the functionality of Axin by associating with it. Thus, Axin gets localized to those areas where it is most crucial to forming axin filaments that are further required for fibroblast and immune cell migration.
Thus, BPC-157 & TB-500 blend synergize to enhance the expression and function of actin and promote faster migration of cells to the areas of damage. Individually, TB-500 use has long been advocated in myocardial infarction. This result is due to its involvement in cardiac muscle repair in injured tissues. It reverses the cardiac damage by increasing blood vessel growth in injured tissues and activating a cardiac response that promotes healing of the cardiac tissue after an event of myocardial infarction. TB-500 has also shown to be of help in patients with cystic fibrosis due to its effect on sputum’s cohesivity, which is decreased after TB-500 administration. TB-500 has a stimulatory effect on myoblasts and myocytes.
Increased levels of TB-500 have been associated with reduced inflammation at the injury site, thereby promoting skeletal muscle regeneration after an injury or insult. It also relieves delayed onset muscle soreness, reduces inflammation, and improves tendon and muscle aches.
BPC-157 is also known as body protection compound-157. This pentadecapeptide comprises 15 amino acids and is similar in structure to the human BPC, which is mainly present in gastric juice. BPC-157 mainly has healing properties. Lab studies on rats have shown healing of a transacted Achilles tendon in the presence of elevated levels of BPC-157. BPC-157 has also been proved to stimulate blood flow, modulate nitric oxide levels in the body, and heal stomach ulcers and intestinal injuries.
Growth Hormone is involved in the Synergism
Growth hormone is a critical mediator in the synergism between BPC-157 and TB-500 for effective wound healing because both molecules interact with the growth hormone during the healing process. BPC-157 induces a higher production of growth hormone receptors on fibroblasts’ surfaces, thereby increasing the lifespan of these cells.
This process, in turn, promotes the regeneration of soft tissues. TB-500 further improves the localization of actin and filament formation. It ensures that the actin reserve is well maintained for use by fibroblasts in their extended lifespans. Thus, BPC-157 & TB-500 blend, collagen, and growth hormones can form an effective alternative treatment regimen for faster wound healing with the potential to replace the existing treatment of choice.
- Lee, E., & Padgett, B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine, 27(4), 8–13.
- Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 110(3), 774–780. https://doi.org/10.1152/japplphysiol.00945.2010
- Moon, E. Y., Im, Y. S., Ryu, Y. K., & Kang, J. H. (2010). Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator. Clinical & experimental metastasis, 27(8), 601–609. https://doi.org/10.1007/s10585-010-9350-z
- Zhou, B., Honor, L. B., Ma, Q., Oh, J. H., Lin, R. Z., Melero-Martin, J. M., von Gise, A., Zhou, P., Hu, T., He, L., Wu, K. H., Zhang, H., Zhang, Y., & Pu, W. T. (2012). Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. Journal of molecular and cellular cardiology, 52(1), 43–47. https://doi.org/10.1016/j.yjmcc.2011.08.020
- Tokura, Y., Nakayama, Y., Fukada, S., Nara, N., Yamamoto, H., Matsuda, R., & Hara, T. (2011). Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of biochemistry, 149(1), 43–48. https://doi.org/10.1093/jb/mvq115
- Chang, C. H., Tsai, W. C., Hsu, Y. H., & Pang, J. H. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (Basel, Switzerland), 19(11), 19066–19077. https://doi.org/10.3390/molecules191119066
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.